Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Journal: Cardiovascular drugs and therapy
Published: September 02, 2021
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.
Journal: Diabetes & metabolic syndrome
Published: August 05, 2021
Not only how much, but also how to, when measuring epicardial adipose tissue.
Journal: Magnetic resonance imaging
Published: June 07, 2021
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Journal: JACC. Heart failure
Published: February 19, 2021
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Journal: Journal of the American College of Cardiology
Published: October 05, 2020
Showing 1-5 of 5
Last Updated: 09/26/2026